Skip to main content
Top
Published in: Current Neurology and Neuroscience Reports 1/2012

01-02-2012 | Nerve and Muscle (M Hirano and LH Weimer, Section Editors)

Advances in the Laboratory Evaluation of Peripheral Neuropathies

Authors: Mengjing Chloe Huan, Mark Bromberg

Published in: Current Neurology and Neuroscience Reports | Issue 1/2012

Login to get access

Abstract

Peripheral neuropathy is a common clinical problem in neurology and laboratory testing is an integral part of diagnosis. In the past few years, practice parameters have been published to establish an evidence-based guide to neuropathy testing. There are many tests that are common and accepted in practice, but there is no clear mandate on which tests are necessary. This article reviews recent practice parameter publications as well as other updates in laboratory testing for peripheral neuropathy, including the roles of lipid profile, genetic testing, antibody titers, and B12 testing in a specific dopamine-treated Parkinson’s patients. These can serve as recommendations to help guide laboratory testing.
Literature
1.
go back to reference •• England JD, Gronseth GS, Franklin G, et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Neurol. 2009;72:185–192. This article provides the first practice parameter guideline for evaluation of the most common pattern of neuropathy, distal symmetric sensory-predominant neuropathy, and testing for complicated genetic testing. CrossRef •• England JD, Gronseth GS, Franklin G, et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Neurol. 2009;72:185–192. This article provides the first practice parameter guideline for evaluation of the most common pattern of neuropathy, distal symmetric sensory-predominant neuropathy, and testing for complicated genetic testing. CrossRef
2.
go back to reference Kahn SN, Bina M. Sensitivity of immunofixation electrophoresis for detecting IgM paraproteins in serum. Clin Chem. 1988;34:1633–5.PubMed Kahn SN, Bina M. Sensitivity of immunofixation electrophoresis for detecting IgM paraproteins in serum. Clin Chem. 1988;34:1633–5.PubMed
3.
go back to reference Azad N, Emanuele NV, Abraira C, et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). J Diabetes Complicat. 1999;13:303–13.CrossRef Azad N, Emanuele NV, Abraira C, et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). J Diabetes Complicat. 1999;13:303–13.CrossRef
4.
go back to reference Tesfaye S, Chatervedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352:341–50.PubMedCrossRef Tesfaye S, Chatervedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352:341–50.PubMedCrossRef
5.
go back to reference Wiggins TD, Sullivan KA, Pop-Busui R, et al. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes. 2009;58:1634–40.CrossRef Wiggins TD, Sullivan KA, Pop-Busui R, et al. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes. 2009;58:1634–40.CrossRef
6.
go back to reference Vincent AM, Hinder LM, Pop-Busui R, Feldman EL. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Periph Nerv Syst. 2009;14:257–67.CrossRef Vincent AM, Hinder LM, Pop-Busui R, Feldman EL. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Periph Nerv Syst. 2009;14:257–67.CrossRef
7.
go back to reference Davis TM, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia. 2008;51(4):562–6.PubMedCrossRef Davis TM, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia. 2008;51(4):562–6.PubMedCrossRef
8.
go back to reference Hou R, Goldberg AC, Tobin GS. A case of severe neuropathy associated with hypertriglyceridemia. Endo Pract. 2008;14(8):1020–2. Hou R, Goldberg AC, Tobin GS. A case of severe neuropathy associated with hypertriglyceridemia. Endo Pract. 2008;14(8):1020–2.
9.
go back to reference Rajabally YA, Shah RS. Dyslipidemia in chronic acquire distal axonal polyneuropathy. J Neurol. 2011;(Epub ahead of print). Rajabally YA, Shah RS. Dyslipidemia in chronic acquire distal axonal polyneuropathy. J Neurol. 2011;(Epub ahead of print).
10.
go back to reference Yiu EM, Geenvasinga N, Nicholson GA, et al. A retrospective review of X-linked Charcot-Marie-Tooth disease in childhood. Neurol. 2011;76(5):461–6.CrossRef Yiu EM, Geenvasinga N, Nicholson GA, et al. A retrospective review of X-linked Charcot-Marie-Tooth disease in childhood. Neurol. 2011;76(5):461–6.CrossRef
11.
go back to reference Saporta ASD, Sottile SL, Miller LJ, et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol. 2011;69:22–33.PubMedCrossRef Saporta ASD, Sottile SL, Miller LJ, et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol. 2011;69:22–33.PubMedCrossRef
12.
go back to reference Feely SM, Laura M, Siskind CE, et al. MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurol. 2011;76(20):1690–6.CrossRef Feely SM, Laura M, Siskind CE, et al. MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurol. 2011;76(20):1690–6.CrossRef
13.
go back to reference • Reilly MM, Shy ME. Diagnosis and new treatments in genetic neuropathies. J Neurol Neurosurg Psychiatry. 2009;80:1304–14. This article reviews genetic testing for common and some uncommon types of hereditary neuropathies, in further depth than the practice parameter on genetic testing. PubMedCrossRef • Reilly MM, Shy ME. Diagnosis and new treatments in genetic neuropathies. J Neurol Neurosurg Psychiatry. 2009;80:1304–14. This article reviews genetic testing for common and some uncommon types of hereditary neuropathies, in further depth than the practice parameter on genetic testing. PubMedCrossRef
14.
go back to reference Marchesi C, Milani M, Morbin M, et al. Four novel cases of periaxin-related neuropathy and review of literature. Neurol. 2010;75(20):1830–8.CrossRef Marchesi C, Milani M, Morbin M, et al. Four novel cases of periaxin-related neuropathy and review of literature. Neurol. 2010;75(20):1830–8.CrossRef
15.
go back to reference Dobourg O, Azzedin H, Verny C, et al. Autosomal-recessive forms of demyelinating Charcot-Marie-Tooth disease. Neuromol Med. 2006;8:75–86.CrossRef Dobourg O, Azzedin H, Verny C, et al. Autosomal-recessive forms of demyelinating Charcot-Marie-Tooth disease. Neuromol Med. 2006;8:75–86.CrossRef
16.
go back to reference Bernard R, De Sandre-Giovannoli A, Delague V, et al. Molecular genetics of autosomal- recessive axonal Charcot-Marie-Tooth neuropathies. Neuromol Med. 2006;8:87–106.CrossRef Bernard R, De Sandre-Giovannoli A, Delague V, et al. Molecular genetics of autosomal- recessive axonal Charcot-Marie-Tooth neuropathies. Neuromol Med. 2006;8:87–106.CrossRef
17.
go back to reference Kissel JT. Autoantibody testing in the evaluation of peripheral neuropathy. Sem Neurol. 1998;18(1):83–94.CrossRef Kissel JT. Autoantibody testing in the evaluation of peripheral neuropathy. Sem Neurol. 1998;18(1):83–94.CrossRef
18.
go back to reference Kornberg AJ, Pestronk A. Antibody-associated polyneuropathy syndromes: principles and treatment. Sem Neurol. 2003;23(2):181–9.CrossRef Kornberg AJ, Pestronk A. Antibody-associated polyneuropathy syndromes: principles and treatment. Sem Neurol. 2003;23(2):181–9.CrossRef
19.
go back to reference Latov N, Sherman WH, Nemni R, et al. Plasma cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral nerve myelin. N Engl J Med. 1980;303:618–21.PubMedCrossRef Latov N, Sherman WH, Nemni R, et al. Plasma cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral nerve myelin. N Engl J Med. 1980;303:618–21.PubMedCrossRef
20.
go back to reference Niermeijer JM, Fischer K, Eurelings M. Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study. Neurol. 2010;74(5):406–12.CrossRef Niermeijer JM, Fischer K, Eurelings M. Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study. Neurol. 2010;74(5):406–12.CrossRef
21.
go back to reference Pestronk A, Li F, Griffin J, et al. Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin-associated glycoprotein. Neurol. 1991;41(3):357–62. Pestronk A, Li F, Griffin J, et al. Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin-associated glycoprotein. Neurol. 1991;41(3):357–62.
22.
go back to reference Nobile-Orazio E, Gallia F, Terenghi E. How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies? J Neurol Sci. 2008;266(1–2):156–63.PubMedCrossRef Nobile-Orazio E, Gallia F, Terenghi E. How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies? J Neurol Sci. 2008;266(1–2):156–63.PubMedCrossRef
23.
go back to reference Cats EA, Jacobs BC, Yuki N, et al. Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features. Neurol. 2010;75:1961–7.CrossRef Cats EA, Jacobs BC, Yuki N, et al. Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features. Neurol. 2010;75:1961–7.CrossRef
24.
go back to reference Willison HJ, O’Leary CP, Veitch J, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain. 2001;124:1968–77.PubMedCrossRef Willison HJ, O’Leary CP, Veitch J, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain. 2001;124:1968–77.PubMedCrossRef
25.
go back to reference Attarian S, Boucraut J, Hubert AM, et al. Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy. J Neurol Neurosurg Psyc. 2010;81(1):61–4.CrossRef Attarian S, Boucraut J, Hubert AM, et al. Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy. J Neurol Neurosurg Psyc. 2010;81(1):61–4.CrossRef
26.
go back to reference Pestronk A, Choksi R, Bieser K, et al. Treatable gait disorders and polyneuropathy associated with high titer serum IgM binding to antigens that copurify with myelin associated glycoprotein. Muscle Nerve. 1994;17:1293–300.PubMedCrossRef Pestronk A, Choksi R, Bieser K, et al. Treatable gait disorders and polyneuropathy associated with high titer serum IgM binding to antigens that copurify with myelin associated glycoprotein. Muscle Nerve. 1994;17:1293–300.PubMedCrossRef
27.
go back to reference Samarasekera S, Rajabally YA. Demyelinating neuropathy with anti-CRMP5 antibodies predating diagnosis of breast carcinoma: favorable outcome after cancer therapy. Muscle Nerve. 2011;43(5):764–6.PubMedCrossRef Samarasekera S, Rajabally YA. Demyelinating neuropathy with anti-CRMP5 antibodies predating diagnosis of breast carcinoma: favorable outcome after cancer therapy. Muscle Nerve. 2011;43(5):764–6.PubMedCrossRef
28.
go back to reference Tschernatsch M, Singh P, Gross O, et al. Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy. J Immunol. 2010;226:177–80. Tschernatsch M, Singh P, Gross O, et al. Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy. J Immunol. 2010;226:177–80.
29.
go back to reference Toth C, Brown MS, Furtado S, et al. Neuropathy as a potential complication of levodopa use in Parkinson’s disease. Mov Disord. 2008;23:1850–9.PubMedCrossRef Toth C, Brown MS, Furtado S, et al. Neuropathy as a potential complication of levodopa use in Parkinson’s disease. Mov Disord. 2008;23:1850–9.PubMedCrossRef
30.
go back to reference Toth C, Breithaupt K, Shaohua GE, et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol. 2010;67:28–36.CrossRef Toth C, Breithaupt K, Shaohua GE, et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol. 2010;67:28–36.CrossRef
31.
go back to reference Urban P, Wellach I, Faiss S, et al. Subacute axonal neuropathy in Parkinson’s diseases with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord. 2010;25:1748–52.PubMedCrossRef Urban P, Wellach I, Faiss S, et al. Subacute axonal neuropathy in Parkinson’s diseases with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord. 2010;25:1748–52.PubMedCrossRef
32.
Metadata
Title
Advances in the Laboratory Evaluation of Peripheral Neuropathies
Authors
Mengjing Chloe Huan
Mark Bromberg
Publication date
01-02-2012
Publisher
Current Science Inc.
Published in
Current Neurology and Neuroscience Reports / Issue 1/2012
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-011-0239-2

Other articles of this Issue 1/2012

Current Neurology and Neuroscience Reports 1/2012 Go to the issue

Nerve and Muscle (M Hirano and LH Weimer, Section Editors)

Update on Toxic Myopathies

Nerve and Muscle (M Hirano and LH Weimer, Section Editors)

Pain Disorders and Erythromelalgia Caused by Voltage-Gated Sodium Channel Mutations

Nerve and Muscle (M Hirano and LH Weimer, Section Editors)

An Update on Monoclonal Gammopathy and Neuropathy

Nerve and Muscle (M Hirano and LH Weimer, Section Editors)

New Therapeutic Approaches to Spinal Muscular Atrophy